Properties of a highly purified human plasma factor IX: c therapeutic concentrate prepared by conventional chromatography

T. Burnouf, C. Michalski, M. Goudemand, J. J. Huart

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

We have characterized a highly purified (HP) factor IX concentrate intended for therapy of hemophilia B. The product has been prepared from pooled human plasma using a large-scale procedure combining three conventional chromatographic steps based based on DEAE ion exchange and affinity on immobilized heparin. The specific activity of the product was 119 ± 10 IU factor IX:c/mg protein (n = 15), corresponding to a purification factor of about 9,000. The concentrate was free of the vitamin K-dependent clotting factors II, VII and X and of proteins C and S. Most of the contaminants found in factor IX complex concentrate (PCC) were absent in this new product. High-molecular-weight kininogen, factors VIII, XI, XII or prekallikrein were not detected. There were no activated factors, such as factors IXa, and Xa, no thrombin and no phospholipids. Only two contaminants could be detected: C4 and inter-alpha-trypsin inhibitor (about 0.8 and 1.2 mg/1,000 IU factor IX:c, respectively). The purity of the product, as compared to PCC, was confirmed by sodium dodecylsulfate polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, Grabar-Williams immunoelectrophoresis, and bidimensional immunoelectrophoresis. Thrombogenicity tests in rabbits revealed that the HP factor IX tested had a lower thrombogenic power than the PCC tested. The concentrate has been subjected to a 0.3% tri(n-butyl) phosphate-1% Tween 80 treatment for 6 h at 25°C during its production to reduce or eliminate the risk of transmission of plasma-borne lipid-enveloped viruses. These conditions inactivated more than 3.8 log10 of vesicular stomatitis virus and more than 4.3 log10 of sindbis virus within 1 and 2 h of treatment, respectively. These data demonstrate that a highly purified therapeutic clotting factor IX concentrate can be prepared from human plasma by conventional chromatographic methods.

Original languageEnglish
Pages (from-to)225-232
Number of pages8
JournalVox Sanguinis
Volume57
Issue number4
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

Factor IX
Chromatography
Immunoelectrophoresis
Blood Coagulation Factors
Factor IXa
High Molecular Weight Kininogens
Factor XI
Prekallikrein
Cellulose Acetate Electrophoresis
Sindbis Virus
Viruses
Hemophilia B
Factor X
Vesicular Stomatitis
Factor VII
Factor Xa
Vitamin K
Polysorbates
Ion Exchange
Protein S

ASJC Scopus subject areas

  • Hematology

Cite this

Properties of a highly purified human plasma factor IX : c therapeutic concentrate prepared by conventional chromatography. / Burnouf, T.; Michalski, C.; Goudemand, M.; Huart, J. J.

In: Vox Sanguinis, Vol. 57, No. 4, 1989, p. 225-232.

Research output: Contribution to journalArticle

@article{2b44ec071189471a9d8f6ba19c91f5e7,
title = "Properties of a highly purified human plasma factor IX: c therapeutic concentrate prepared by conventional chromatography",
abstract = "We have characterized a highly purified (HP) factor IX concentrate intended for therapy of hemophilia B. The product has been prepared from pooled human plasma using a large-scale procedure combining three conventional chromatographic steps based based on DEAE ion exchange and affinity on immobilized heparin. The specific activity of the product was 119 ± 10 IU factor IX:c/mg protein (n = 15), corresponding to a purification factor of about 9,000. The concentrate was free of the vitamin K-dependent clotting factors II, VII and X and of proteins C and S. Most of the contaminants found in factor IX complex concentrate (PCC) were absent in this new product. High-molecular-weight kininogen, factors VIII, XI, XII or prekallikrein were not detected. There were no activated factors, such as factors IXa, and Xa, no thrombin and no phospholipids. Only two contaminants could be detected: C4 and inter-alpha-trypsin inhibitor (about 0.8 and 1.2 mg/1,000 IU factor IX:c, respectively). The purity of the product, as compared to PCC, was confirmed by sodium dodecylsulfate polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, Grabar-Williams immunoelectrophoresis, and bidimensional immunoelectrophoresis. Thrombogenicity tests in rabbits revealed that the HP factor IX tested had a lower thrombogenic power than the PCC tested. The concentrate has been subjected to a 0.3{\%} tri(n-butyl) phosphate-1{\%} Tween 80 treatment for 6 h at 25°C during its production to reduce or eliminate the risk of transmission of plasma-borne lipid-enveloped viruses. These conditions inactivated more than 3.8 log10 of vesicular stomatitis virus and more than 4.3 log10 of sindbis virus within 1 and 2 h of treatment, respectively. These data demonstrate that a highly purified therapeutic clotting factor IX concentrate can be prepared from human plasma by conventional chromatographic methods.",
author = "T. Burnouf and C. Michalski and M. Goudemand and Huart, {J. J.}",
year = "1989",
language = "English",
volume = "57",
pages = "225--232",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Properties of a highly purified human plasma factor IX

T2 - c therapeutic concentrate prepared by conventional chromatography

AU - Burnouf, T.

AU - Michalski, C.

AU - Goudemand, M.

AU - Huart, J. J.

PY - 1989

Y1 - 1989

N2 - We have characterized a highly purified (HP) factor IX concentrate intended for therapy of hemophilia B. The product has been prepared from pooled human plasma using a large-scale procedure combining three conventional chromatographic steps based based on DEAE ion exchange and affinity on immobilized heparin. The specific activity of the product was 119 ± 10 IU factor IX:c/mg protein (n = 15), corresponding to a purification factor of about 9,000. The concentrate was free of the vitamin K-dependent clotting factors II, VII and X and of proteins C and S. Most of the contaminants found in factor IX complex concentrate (PCC) were absent in this new product. High-molecular-weight kininogen, factors VIII, XI, XII or prekallikrein were not detected. There were no activated factors, such as factors IXa, and Xa, no thrombin and no phospholipids. Only two contaminants could be detected: C4 and inter-alpha-trypsin inhibitor (about 0.8 and 1.2 mg/1,000 IU factor IX:c, respectively). The purity of the product, as compared to PCC, was confirmed by sodium dodecylsulfate polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, Grabar-Williams immunoelectrophoresis, and bidimensional immunoelectrophoresis. Thrombogenicity tests in rabbits revealed that the HP factor IX tested had a lower thrombogenic power than the PCC tested. The concentrate has been subjected to a 0.3% tri(n-butyl) phosphate-1% Tween 80 treatment for 6 h at 25°C during its production to reduce or eliminate the risk of transmission of plasma-borne lipid-enveloped viruses. These conditions inactivated more than 3.8 log10 of vesicular stomatitis virus and more than 4.3 log10 of sindbis virus within 1 and 2 h of treatment, respectively. These data demonstrate that a highly purified therapeutic clotting factor IX concentrate can be prepared from human plasma by conventional chromatographic methods.

AB - We have characterized a highly purified (HP) factor IX concentrate intended for therapy of hemophilia B. The product has been prepared from pooled human plasma using a large-scale procedure combining three conventional chromatographic steps based based on DEAE ion exchange and affinity on immobilized heparin. The specific activity of the product was 119 ± 10 IU factor IX:c/mg protein (n = 15), corresponding to a purification factor of about 9,000. The concentrate was free of the vitamin K-dependent clotting factors II, VII and X and of proteins C and S. Most of the contaminants found in factor IX complex concentrate (PCC) were absent in this new product. High-molecular-weight kininogen, factors VIII, XI, XII or prekallikrein were not detected. There were no activated factors, such as factors IXa, and Xa, no thrombin and no phospholipids. Only two contaminants could be detected: C4 and inter-alpha-trypsin inhibitor (about 0.8 and 1.2 mg/1,000 IU factor IX:c, respectively). The purity of the product, as compared to PCC, was confirmed by sodium dodecylsulfate polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, Grabar-Williams immunoelectrophoresis, and bidimensional immunoelectrophoresis. Thrombogenicity tests in rabbits revealed that the HP factor IX tested had a lower thrombogenic power than the PCC tested. The concentrate has been subjected to a 0.3% tri(n-butyl) phosphate-1% Tween 80 treatment for 6 h at 25°C during its production to reduce or eliminate the risk of transmission of plasma-borne lipid-enveloped viruses. These conditions inactivated more than 3.8 log10 of vesicular stomatitis virus and more than 4.3 log10 of sindbis virus within 1 and 2 h of treatment, respectively. These data demonstrate that a highly purified therapeutic clotting factor IX concentrate can be prepared from human plasma by conventional chromatographic methods.

UR - http://www.scopus.com/inward/record.url?scp=0024378768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024378768&partnerID=8YFLogxK

M3 - Article

C2 - 2617959

AN - SCOPUS:0024378768

VL - 57

SP - 225

EP - 232

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 4

ER -